OPKO Health (OPK) Jefferies 2024 Global Healthcare Conference summary

Business overview and recent developments

• Diversified operations include specialty pharmaceuticals, diagnostics, and biotech, with international reach and recent expansion through acquisition of ModeX Therapeutics.

• Diagnostics business restructured post-COVID, downsizing from 8,000 to 4,000 employees and focusing on core regional strengths in New York and New Jersey.

• Sold select diagnostic assets outside New Jersey to Labcorp for $237.5 million, retaining oncology and urology segments.

• Targeting breakeven for diagnostics by mid-2024 and positive cash flow by year-end, with further profitability expected in 2025.

• Ongoing evaluation of additional M&A opportunities to maximize value and profitability.

Diagnostics and product performance

• 4Kscore test is profitable, growing at 10% annually, with plans for international expansion and enhanced marketing through Labcorp collaboration.

• Oncology segment is strong, with new contracts and improved reimbursement for genomic testing; focus remains on New York and New Jersey.

• Women's health largely divested; urology and 4Kscore test expansion continue.

Specialty pharmaceuticals and international growth

• Specialty pharma business outside the U.S. is stable, growing 8–10% annually with 15–20% EBITDA margins.

• Expansion considered opportunistically, with organic growth as a baseline strategy.